Endpoints News· @endpts · X·· 27 天前精选AI 评分78
AI 导读
GSK的Hibsago获FDA批准,被视为乙肝的潜在功能性治愈方案。该药带有黑框警告,可能限制其市场吸引力。
推荐理由
GSK的乙肝药物获FDA批准并带黑框警告,读者可据此判断其潜在功能治愈定位与安全性限制之间的张力。
正文
GSK's Hibsago won FDA approval as a potential functional cure for hepatitis B, but a black box warning could limit its appeal.
https://endpoints.news/gsk-gets-fda-approval-for-hepatitis-b-drug-that-offers-functional-cure/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com